2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07E.03 TP53 Co-Mutations Increase Risk of Recurrence in EGFR-Mutated Stage I Lung Adenocarcinoma

Pdf Summary

The study, conducted by Filippo Tommaso Gallina from the Division of Thoracic Surgery at McGill University Health Centre, examines the impact of TP53 co-mutations on the recurrence risk in patients with early-stage lung adenocarcinoma (LUAD) who harbor EGFR mutations. EGFR mutations are noted as a common oncogenic driver in LUAD, with their prevalence varying significantly between Western Europe and East Asia. Despite advances in understanding through trials like ADAURA, the prognostic role of EGFR mutations in early-stage non-small cell lung cancer (NSCLC) is still not fully understood. <br /><br />To explore this, the researchers analyzed data from 389 patients who had undergone radical surgical treatment for stage I LUAD across two high-volume centers. Multivariate Cox regression, Kaplan-Meier survival analysis, and log-rank testing were employed to assess disease-free survival (DFS) in these patients. Key findings highlighted that EGFRTP53 co-mutations significantly diminish DFS when compared to patients with EGFR wild-type and EGFR single mutations.<br /><br />The study also identified other factors adversely affecting DFS, including a history of smoking, presence of pT3 tumors, and MET amplification. Significantly, the hazard ratio for EGFRTP53 co-mutations was 3.84, indicating a higher risk of recurrence or death for patients with these genetic profiles.<br /><br />In conclusion, the research underscores the aggressive nature of EGFRTP53 co-mutations in early-stage LUAD, suggesting they are a biomarker for poor prognosis. This contributes to a better understanding of molecular characteristics that affect recurrence and survival, highlighting the need for attentive post-operative monitoring and possibly more aggressive treatment strategies for patients with these mutations.

Asset Subtitle

Filippo Tommaso Gallina

Meta Tag

Speaker Filippo Tommaso Gallina

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

TP53 co-mutations

EGFR mutations

lung adenocarcinoma

LUAD

disease-free survival

non-small cell lung cancer

NSCLC

prognostic role

biomarker

recurrence risk